Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Disposition of L-732,531, a Potent Immunosuppressant, in Rats and Baboons

B. V. Karanam, R. R. Miller, A. Colletti, T. Montgomery, K. D. Carey, T. Hawkins, Y. S. Tang, M. Lavin, R. A. Stearns, S. H. L. Chiu and S. H. Vincent
Drug Metabolism and Disposition October 1998, 26 (10) 949-957;
B. V. Karanam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. R. Miller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Colletti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Montgomery
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. D. Carey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Hawkins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. S. Tang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Lavin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. A. Stearns
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. H. L. Chiu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. H. Vincent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

L-732,531 is a semi-synthetic analog of the macrolide tacrolimus (Prograf®). Like tacrolimus, L-732,531 is a potent immunosuppressant. In this study, its absorption, distribution, metabolism, and excretion were studied in rats and baboons. In rats, its blood and plasma levels were similar, whereas in baboons, its blood levels were, on average, twice as high as those in plasma. This was consistent with the in vitro blood-to-plasma ratio of L-732,531, which in these two species, as well as in humans, was much lower than that of tacrolimus and showed a minimal concentration dependence. After iv administration to rats, the blood and plasma clearance of L-732,531 decreased from ∼60 ml/min/kg at 0.2 mg/kg to 30 ml/min/kg when dosed at 1 and 3 mg/kg. After oral administration, plasma area under the concentration vs. time curve (AUC) and maximal plasma concentration (Cmax) increased more than proportionally to the dose. At 1, 5, and 15 mg/kg, plasma AUC was 29, 466, and 2832 ng·hr/ml, respectively, andCmax was 10, 129, and 304 ng/ml, respectively. Bioavailability, although compromised by nonlinear kinetics, was estimated to be between 8% and 18%. In baboons, the clearance of L-732,531 was lower than that in rats, especially when calculated from blood concentrations (12 ml/min/kg at 0.2 mg/kg and 8 ml/min/kg at 1 mg/kg). After oral dosing, baboon plasma AUC andCmax were much lower than those in rats, but as in rats, they increased more than proportionally with increasing doses. The bioavailability of L-732,531 in baboons was estimated at 3%, 9%, and 24% when animals were dosed at 5, 15, and 26 mg/kg po, respectively. After oral administration of [3H]L-732,531 at 5 mg/kg, ∼32% of the radioactivity was recovered in bile and urine of rats, compared with 9% in baboons. High-performance liquid chromatography profiles of rat and baboon plasma, bile, urine, and feces indicated that L-732,531 was metabolized extensively to a complex mixture of products. Some intact parent drug was observed in feces of orally dosed animals, indicating incomplete absorption. In vitro, L-732,531 was metabolized more extensively by baboon liver microsomes than rat or human microsomes. Its metabolism in human liver microsomes was shown to be catalyzed primarily by cytochrome P450 3A isozymes.

Footnotes

  • Send reprint requests to: Dr. Stella Vincent, Merck Research Laboratories, RY 80L109, P.O. Box 200, Rahway, NJ 07065.

  • ↵1 Abbreviations used are: HPLC, high-performance liquid chromatography; CYP or P450, cytochrome P450; LC-MS/MS, liquid chromatography–tandem mass spectrometry; MS, mass spectroscopy; Cmax, maximal plasma concentration; AUC, area under the concentration vs. time curve; FKBP12, FK506-binding protein; TFA, trifluoroacetic acid.

    • Received October 15, 1997.
    • Accepted April 15, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition
Vol. 26, Issue 10
1 Oct 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Disposition of L-732,531, a Potent Immunosuppressant, in Rats and Baboons
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Disposition of L-732,531, a Potent Immunosuppressant, in Rats and Baboons

B. V. Karanam, R. R. Miller, A. Colletti, T. Montgomery, K. D. Carey, T. Hawkins, Y. S. Tang, M. Lavin, R. A. Stearns, S. H. L. Chiu and S. H. Vincent
Drug Metabolism and Disposition October 1, 1998, 26 (10) 949-957;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Disposition of L-732,531, a Potent Immunosuppressant, in Rats and Baboons

B. V. Karanam, R. R. Miller, A. Colletti, T. Montgomery, K. D. Carey, T. Hawkins, Y. S. Tang, M. Lavin, R. A. Stearns, S. H. L. Chiu and S. H. Vincent
Drug Metabolism and Disposition October 1, 1998, 26 (10) 949-957;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CES2-based hydrolysis of molnupiravir
  • Oral PBPK Modeling of Vismodegib
  • Transporter-enzyme interplay in PK of PF-06835919
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics